Implementation and expansion of laboratory capacity for molecular diagnostics in response to COVID‐19 and preparedness for other emerging infectious diseases in the Islamic Emirate of Afghanistan

Author:

Khan Murad Momin1,Tahoun Mohamed Mostafa12,Meredith Luke W.3ORCID,Barakat Amal3,Safi Hafizullah1,Hanifi Ahmed Nasir4,Mashal Mohammad Omar1,Amiri Abdul Wahid1,Abouzeid Alaa15

Affiliation:

1. Afghanistan Country Office World Health Organization Kabul Afghanistan

2. High Institute of Public Health Alexandria University Alexandria Egypt

3. Eastern Mediterranean Regional Office World Health Organization Cairo Egypt

4. Directorate of Diagnostic Services Ministry of Public Health Kabul Afghanistan

5. Faculty of Medicine Cairo University Cairo Egypt

Abstract

AbstractBackgroundAfghanistan experienced various outbreaks before and during the Covid‐19 pandemic, including dengue, Crimean Congo hemorrhagic fever (CCHF), measles, and acute watery diarrhea (AWD). Diagnostic and surveillance support was limited, with only the Central Public Health Laboratory equipped to handle outbreak responses. This article highlights initiatives taken to improve diagnostic capabilities for COVID‐19 and other outbreaks of public health concern encountered during the pandemic.BackgroundThe World Health Organization (WHO) Afghanistan Country Office collaborated with the WHO Eastern Mediterranean Regional Office (EMRO), Central Public Health Laboratory (CPHL), and National Influenza Center (NIC) to enhance COVID‐19 diagnostic capacity at national and subnational facilities. To alleviate pressure on CPHL, a state‐of‐the‐art laboratory was established at the National Infectious Disease Hospital (NIDH) in Kabul in 2021–2022, while WHO EMRO facilitated the regionalization of testing to subnational facilities for dengue, CCHF, and AWD in 2022–2023.ResultsCOVID‐19 testing capacity expanded nationwide to 34 Biosafety Level II labs, improving diagnosis time. Daily testing rose from 1000 in 2020 to 9200 in 2023, with 848,799 cumulative tests. NIDH identified 229 CCHF cases and 45 cases nationally. Dengue and CCHF testing, decentralized to Nangarhar and Kandahar labs, identified 338 dengue and 18 CCHF cases. AWD testing shifted to NIDH and five subnational facilities (Kandahar, Paktia, Balkh, Herat, and Nangarhar labs), while measles testing also decentralized to nine subnational facilities.ConclusionAfghanistan implemented a remarkable, multisectoral response to priority pathogens. The nation now possesses diagnostic expertise at national and subnational levels, supported by genomic surveillance. Future efforts should concentrate on expanding and sustaining this capacity to enhance public health responses.

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,Epidemiology

Reference10 articles.

1. World Health Organization Countries.https://www.who.int/countries/afg

2. WHO/AFRO.Genome sequencing central to COVID‐19 response.2021.https://www.afro.who.int/news/genome-sequencing-central-covid-19-response

3. Erasmus Medical Center Virology Clinic https://www.erasmusmc.nl/en/patient-care/laboratoriumspecialismen/klinische-virologie

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3